Related Experiment Video
Updated: Jun 20, 2025
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Anticoagulation and compression therapy for proximal acute deep vein thrombosis
Gualtiero Palareti1, Davide Santagata2, Chiara De Ponti2
1Fondazione Arianna, Bologna, Italy.
Insights
Direct oral anticoagulants (DOACs) are the preferred first-line treatment for proximal deep vein thrombosis (DVT). Treatment duration varies, with indefinite anticoagulation recommended for unprovoked DVT or chronic risk factors.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Proximal deep vein thrombosis (DVT) management involves distinct treatment phases: initial (1-3 weeks), primary (≥3 months), and secondary (beyond 3-6 months).
- Outpatient management is feasible for most DVT patients during the initial phase, with specific exclusion criteria for hospitalization.
Purpose of the Study:
- To outline the current treatment strategies for proximal deep vein thrombosis (DVT) of the lower limbs.
- To highlight the role of anticoagulants, particularly direct oral anticoagulants (DOACs), in DVT management.
- To discuss factors influencing anticoagulant choice and the use of elastic compression stockings (ECS).
Main Methods:
- Review of current treatment guidelines and pharmacological options for proximal DVT.
- Analysis of anticoagulant classes, including parenteral (heparin) and oral agents (VKA, DOACs).
- Consideration of patient-specific factors (renal/liver function, comorbidities) and adjunctive therapies like ECS.
Main Results:
- Direct oral anticoagulants (DOACs) are recommended as first-line therapy for proximal DVT, with no specific DOAC preference.
- Indefinite anticoagulation is advised for unprovoked DVT and patients with permanent risk factors.
- Low-dose apixaban and rivaroxaban are options for secondary DVT prevention; ECS aid in managing venous hypertension and edema.
Conclusions:
- DOACs represent the primary treatment for proximal DVT, offering flexibility in outpatient management.
- Treatment duration should be individualized, with extended anticoagulation indicated for specific patient groups.
- Elastic compression stockings serve as an adjunct therapy to mitigate DVT sequelae.
Abstract:
The treatment of proximal deep vein thrombosis (DVT) of the lower limbs includes an initial management phase, covering the first 1 to 3 weeks, a primary treatment phase, lasting a minimum of 3 months, and a secondary treatment phase for those patients requiring continuing anticoagulation beyond the first 3 to 6 months. During the initial phase most patients with DVT can be managed as outpatients. Exclusion criteria for home treatment include high risk of bleeding, limb threatening DVT or other conditions requiring hospitalisation. Anticoagulant drugs represent the mainstay of treatment and include parenteral drugs such as unfractionated heparin or low molecular weight heparin, and oral drugs such as the vitamin K antagonists and the direct oral anticoagulants (DOACs). DOACs are currently recommended as the first line of treatment for proximal DVT of the lower limbs, with no preference for one DOAC over another. Factors to consider when choosing the anticoagulant strategy include, among others, renal and liver function, underlying diseases such as cancer or the antiphospholipid syndrome, and patient preferences. Indefinite duration of anticoagulation beyond the first 3 to 6 months is recommended for patients with unprovoked DVT and patients with permanent, chronic risk factors. Two DOACs, namely apixaban and rivaroxaban, can be administered at low doses for the secondary prevention of DVT. Elastic compression stockings (ECS) have been used for decades in patients with proximal DVT with the aim of counteracting the venous hypertension generated by the vascular disorder and reducing leg edema and to prevent the post-thrombotic syndrome.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Clot Retraction and Fibrinolysis
01:15Veins of Lower Limbs
Formed by the union of the medial and lateral plantar veins, the posterior tibial vein, rising through the calf muscle, assimilates the fibular vein. The anterior tibial vein, a superior extension of the foot's dorsalis pedis vein, merges with the posterior tibial vein at the...
01:04Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
01:16Vascular Spasm